UB Paderborn / Katalog / Suche / in CDI

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial

The lancet oncology, 2013-09, Vol.14 (10), p.989-998

2013

Volltextzugriff (PDF)

Study of Etanercept, a Tumor Necrosis Factor-Alpha Inhibitor, in Recurrent Ovarian Cancer

Journal of clinical oncology, 2005-09, Vol.23 (25), p.5950-5959

2005

Volltextzugriff (PDF)

A Phase II Study of Etanercept (Enbrel), a Tumor Necrosis Factor α Inhibitor in Patients with Metastatic Breast Cancer

Clinical cancer research, 2004-10, Vol.10 (19), p.6528-6534

2004

Volltextzugriff (PDF)

A randomised controlled trial of intravenous zoledronic acid in malignant pleural disease: a proof of principle pilot study

PloS one, 2015-03, Vol.10 (3), p.e0118569-e0118569

2015

Volltextzugriff (PDF)

Phase I Study of MetXia-P450 Gene Therapy and Oral Cyclophosphamide for Patients with Advanced Breast Cancer or Melanoma

Clinical cancer research, 2005-02, Vol.11 (4), p.1512-1520

2005

Volltextzugriff (PDF)

Functional Interaction between the Bloom's Syndrome Helicase and the RAD51 Paralog, RAD51L3 (RAD51D)

The Journal of biological chemistry, 2003-11, Vol.278 (48), p.48357-48366

2003

Volltextzugriff (PDF)

Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group

NPJ breast cancer, 2020-05, Vol.6 (1), p.16, Article 16

2020

Volltextzugriff (PDF)

The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer

Nature (London), 2024-05, Vol.629 (8014), p.1142-1148

2024

Volltextzugriff (PDF)

Low-Dose IFN-γ Induces Tumor MHC Expression in Metastatic Malignant Melanoma

Clinical cancer research, 2003-01, Vol.9 (1), p.84-92

2003

Volltextzugriff (PDF)

The impact of the 21-gene assay on adjuvant treatment decisions in oestrogen receptor-positive early breast cancer: a prospective study

British journal of cancer, 2016-03, Vol.114 (7), p.731-736

2016

Volltextzugriff (PDF)

A Phase II Study of Razoxane, an Antiangiogenic Topoisomerase II Inhibitor, in Renal Cell Cancer with Assessment of Potential Surrogate Markers of Angiogenesis

Clinical cancer research, 2000-12, Vol.6 (12), p.4697-4704

2000

Volltextzugriff (PDF)

Pharmacokinetic Study of Cisplatin and Infusional Etoposide Phosphate in Advanced Breast Cancer with Correlation of Response to Topoisomerase IIα Expression

Clinical cancer research, 2003-10, Vol.9 (13), p.4682-4688

2003

Volltextzugriff (PDF)

Medical and oncological management of malignant mesothelioma

British journal of hospital medicine (London, England : 2005), 2015-07, Vol.76 (7), p.384-389

2015

Volltextzugriff (PDF)

18F-Fluorodeoxyglucose PET/CT and dynamic contrast-enhanced MRI as imaging biomarkers in malignant pleural mesothelioma

Nuclear medicine communications, 2018-02, Vol.39 (2), p.161-170

2018

Volltextzugriff (PDF)

Extended survival in women with brain metastases from HER2 overexpressing breast cancer

American journal of clinical oncology, 2008-06, Vol.31 (3), p.250-254

2008

Volltextzugriff (PDF)

Paraneoplastic tumefactive demyelination with underlying combined germ cell cancer

Practical neurology, 2015-12, Vol.15 (6), p.451-455

2015

Volltextzugriff (PDF)

Antiangiogenic therapy for von Hippel-Lindau disease

JAMA : the journal of the American Medical Association, 2004-02, Vol.291 (8), p.943

2004

Volltextzugriff (PDF)

Phase I Study of Intrapleural Batimastat (BB-94), a Matrix Metalloproteinase Inhibitor, in the Treatment of Malignant Pleural Effusions

Clinical cancer research, 1999-03, Vol.5 (3), p.513-520

1999

Volltextzugriff (PDF)

The RAD51 Family Member, RAD51L3, Is a DNA-stimulated ATPase That Forms a Complex with XRCC2

The Journal of biological chemistry, 2000-09, Vol.275 (37), p.29100-29106

2000

Volltextzugriff (PDF)

Coherent Ultrasonic Doppler Tomography

Ultrasound in medicine & biology, 2011-04, Vol.37 (4), p.642-650

2011

Volltextzugriff (PDF)

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

NPJ breast cancer, 2020-05, Vol.6 (1), p.17-17, Article 17

2020

Volltextzugriff (PDF)

Abstract P1-19-14: Results from plasmaMATCH trial treatment cohort D: A phase II trial of capivasertib in patients with an AKT activation basket mutation identified via ctDNA testing or tumour sequencing (CRUK/15/010)

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P1-P1-19-14

2020

Volltextzugriff (PDF)

Abstract P1-19-04: Results from plasmaMATCH trial treatment cohort A: A phase II trial of extended-dose fulvestrant in patients with an ESR1 mutation identified via ctDNA screening (CRUK/15/010)

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P1-P1-19-04

2020

Volltextzugriff (PDF)

Abstract P1-19-11: Results from plasmaMATCH trial treatment cohort C: A phase II trial of capivasertib plus fulvestrant in ER positive breast cancer patients with an AKT1 mutation identified via ctDNA screening (CRUK/15/010)

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P1-P1-19-11

2020

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial

Study of Etanercept, a Tumor Necrosis Factor-Alpha Inhibitor, in Recurrent Ovarian Cancer

Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial

A Phase II Study of Etanercept (Enbrel), a Tumor Necrosis Factor α Inhibitor in Patients with Metastatic Breast Cancer

A randomised controlled trial of intravenous zoledronic acid in malignant pleural disease: a proof of principle pilot study

Phase I Study of MetXia-P450 Gene Therapy and Oral Cyclophosphamide for Patients with Advanced Breast Cancer or Melanoma

Functional Interaction between the Bloom's Syndrome Helicase and the RAD51 Paralog, RAD51L3 (RAD51D)

Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group

The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer

Low-Dose IFN-γ Induces Tumor MHC Expression in Metastatic Malignant Melanoma

The impact of the 21-gene assay on adjuvant treatment decisions in oestrogen receptor-positive early breast cancer: a prospective study

A Phase II Study of Razoxane, an Antiangiogenic Topoisomerase II Inhibitor, in Renal Cell Cancer with Assessment of Potential Surrogate Markers of Angiogenesis

Pharmacokinetic Study of Cisplatin and Infusional Etoposide Phosphate in Advanced Breast Cancer with Correlation of Response to Topoisomerase IIα Expression

Medical and oncological management of malignant mesothelioma

18F-Fluorodeoxyglucose PET/CT and dynamic contrast-enhanced MRI as imaging biomarkers in malignant pleural mesothelioma

Extended survival in women with brain metastases from HER2 overexpressing breast cancer

Paraneoplastic tumefactive demyelination with underlying combined germ cell cancer

Antiangiogenic therapy for von Hippel-Lindau disease

Phase I Study of Intrapleural Batimastat (BB-94), a Matrix Metalloproteinase Inhibitor, in the Treatment of Malignant Pleural Effusions

The RAD51 Family Member, RAD51L3, Is a DNA-stimulated ATPase That Forms a Complex with XRCC2

Coherent Ultrasonic Doppler Tomography

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

Abstract P1-19-14: Results from plasmaMATCH trial treatment cohort D: A phase II trial of capivasertib in patients with an AKT activation basket mutation identified via ctDNA testing or tumour sequencing (CRUK/15/010)

Abstract P1-19-04: Results from plasmaMATCH trial treatment cohort A: A phase II trial of extended-dose fulvestrant in patients with an ESR1 mutation identified via ctDNA screening (CRUK/15/010)

Abstract P1-19-11: Results from plasmaMATCH trial treatment cohort C: A phase II trial of capivasertib plus fulvestrant in ER positive breast cancer patients with an AKT1 mutation identified via ctDNA screening (CRUK/15/010)

Suchergebnisse filtern